Sanofi India Ltd vs Venmax Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3424 as of 04 May 10:12 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Venmax Drugs & Pharmaceuticals Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Venmax Drugs & Pharmaceuticals Ltd is ₹ 0 crore as of December 2023 . The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Venmax Drugs & Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Venmax Drugs & Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Venmax Drugs & Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Venmax Drugs & Pharmaceuticals Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Venmax Drugs & Pharmaceuticals Ltd

Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Company as 'Yenkay Medico Private Limited', on 28 September, 1998.
The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995.
It became a Public Limited Company on February 3, 1995 as 'Yenkey Drugs & Pharmaceuticals Limited'.
Finally, the Company changed its name to 'Venmax Drugs & Pharmaceuticals Limited' on April 13, 2009. For the past six months, Company focused on establishing chain of Medical Stores with a brand name as 'Ananya Pharma' under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs).
At present, Company is engaged in the business of pharmaceutical products, drug intermediaries & API's etc. The Company is developing the oncology products in R&D.

FAQs for the comparison of Sanofi India Ltd and Venmax Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Venmax Drugs & Pharmaceuticals Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Venmax Drugs & Pharmaceuticals Ltd is 28 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Venmax Drugs & Pharmaceuticals Ltd?

The stock performance of Sanofi India Ltd and Venmax Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Venmax Drugs & Pharmaceuticals Ltd?

As of May 4, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Venmax Drugs & Pharmaceuticals Ltd stock price is INR ₹24.51.

How do dividend payouts of Sanofi India Ltd and Venmax Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Venmax Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.